SAN DIEGO, April 11, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that the Company has received official notification from the U.S. Patent and Trademark Office that U.S. Patent No. 7,816,379 which covers the composition of matter of torezolid phosphate (TR-701), the Company's lead investigational drug, has been extended by one thousand one hundred sixty-three (1,163) days. The patent term adjustment granted by the U.S. Patent and Trademark Office extends patent coverage in the United States on torezolid phosphate until February 23, 2028.
